NEW YORK — BGI Americas said on Tuesday that it has signed an agreement to market its PCR-based SARS-CoV-2 detection kit with Advaite's RapCov COVID-19 immunoassay to hospitals and healthcare facilities.
BGI America's Real-Time Fluorescent RT-PCR Kit is designed to detect SARS-CoV-2 nucleic acid in throat swabs and bronchoalveolar lavage fluid in approximately three hours. It received Emergency Use Authorization from the US Food and Drug Administration in early 2020.
The RapCov Rapid COVID-19 Test is a lateral flow assay designed to detect IgG against SARS-CoV-2 using a fingerstick blood sample in point-of-care settings, providing results in 15 minutes. Malvern, Pennsylvania-based Advaite received FDA EUA for the test in January of this year.
San Jose-based BGI Americas said that offering the assays together will provide customers with both central laboratory and point-of-care CLIA-waived testing options for SARS-CoV-2 testing.
Financial and other terms of the partnership were not disclosed.
BGI Americas also said that it has launched a website through which it solicits licensing, original equipment manufacturer, or distribution agreements with other diagnostic companies for their products.